Free Trial
Notice: This company recently went public with an IPO on Friday, September 13th 2024. They issued 17,500,000 shares at $18.00 per share. We will continue to update data for BCAX as it becomes available.
NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

$25.73
-1.34 (-4.95%)
(As of 09/18/2024 ET)

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$24.80
$27.47
50-Day Range
N/A
52-Week Range
$21.05
$27.94
Volume
299,459 shs
Average Volume
502,486 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $25.41 at the beginning of 2024. Since then, BCAX stock has increased by 1.3% and is now trading at $25.73.
View the best growth stocks for 2024 here
.

Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

Bicara Therapeutics' quiet period expires on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its initial public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During Bicara Therapeutics' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Fax
N/A
Employees
32
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
N/A
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners